Literature DB >> 9671267

Analysis of recurrent germline mutations in the MEN1 gene encountered in apparently unrelated families.

S K Agarwal1, L V Debelenko, M B Kester, S C Guru, P Manickam, S E Olufemi, M C Skarulis, C Heppner, J S Crabtree, I A Lubensky, Z Zhuang, Y S Kim, S C Chandrasekharappa, F S Collins, L A Liotta, A M Spiegel, A L Burns, M R Emmert-Buck, S J Marx.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder that manifests as varying combinations of tumors of endocrine and other tissues (parathyroids, pancreatic islets, duodenal endocrine cells, the anterior pituitary and others). The MEN1 gene is on chromosome 11q13; it was recently identified by positional cloning. We previously reported 32 different germline mutations in 47 of the 50 familial MEN1 probands studied at the NIH. Eight different germline MEN1 mutations were encountered repeatedly in two or more apparently unrelated families. We analyzed the haplotypes of families with recurrent MEN1 mutations with seven polymorphic markers in the 11q13 region surrounding the MEN1 gene (from D11S1883 to D11S4908). Disease haplotypes were inferred from germline DNA and also from tumors with 11ql3 loss of heterozygosity. Two different disease haplotype cores were shared by apparently unrelated families for two mutations in exon 2 (five families with 416delC and six families with 512delC). These two repeat mutations were associated with the two founder effects that we reported in a prior haplotype analysis. The disease haplotypes for each of the other six repeat mutations (seen twice each) were discordant, suggesting independent origins of these recurrent mutations. Most of the MEN1 germline mutations including all of those recurring independently occur in regions of CpG/CpNpG, short DNA repeats or single nucleotide repeat motifs. In conclusion, recurring germline mutations account for about half of the mutations in North American MEN1 families. They result from either founder effects or independent occurrence of one mutation more than one time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671267     DOI: 10.1002/(SICI)1098-1004(1998)12:2<75::AID-HUMU1>3.0.CO;2-T

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Amit Tirosh; Sanjit Mukherjee; Justin Lack; Sudheer Kumar Gara; Sophie Wang; Martha M Quezado; Xavier M Keutgen; Xiaolin Wu; Maggie Cam; Suresh Kumar; Dhaval Patel; Naris Nilubol; Monica Varun Tyagi; Electron Kebebew
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

2.  Persistently Elevated PTH After Parathyroidectomy at One Year: Experience in a Tertiary Referral Center.

Authors:  Marie Caldwell; Jeff Laux; Marshall Clark; Lawrence Kim; Janet Rubin
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 3.  The MEN1 gene and associated diseases: an update.

Authors:  T Tsukada; K Yamaguchi; T Kameya
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  Cladistic structure within the human Lipoprotein lipase gene and its implications for phenotypic association studies.

Authors:  A R Templeton; K M Weiss; D A Nickerson; E Boerwinkle; C F Sing
Journal:  Genetics       Date:  2000-11       Impact factor: 4.562

5.  Of mice and MEN1: Insulinomas in a conditional mouse knockout.

Authors:  Judy S Crabtree; Peter C Scacheri; Jerrold M Ward; Sara R McNally; Gary P Swain; Cristina Montagna; Jeffrey H Hager; Douglas Hanahan; Helena Edlund; Mark A Magnuson; Lisa Garrett-Beal; A Lee Burns; Thomas Ried; Settara C Chandrasekharappa; Stephen J Marx; Allen M Spiegel; Francis S Collins
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

Review 6.  The future: genetics advances in MEN1 therapeutic approaches and management strategies.

Authors:  Sunita K Agarwal
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

7.  EXPRESSION OF MENIN IN THE HUMAN THYROID GLAND.

Authors:  O M Capraru; M Decaussin-Petrucci; M O Joly; A Borda; I S Fanfaret; F Borson-Chazot; S Selmi-Ruby
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.